PeterH.SayreMD

Professor, Diabetes Center, UCSF School of Medicine

Dr. Sayre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
400 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2421

Fax+1 415-353-2467

University of California (San Diego) Medical CenterResidency, Internal Medicine, 1990 - 1993
Rutgers Robert Wood Johnson Medical SchoolClass of 1990

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

186 citations
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt
Blood. 2021-02-11
21 citations
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results
Matthew J. Wieduwilt, Nela Pawlowska, Scott Thomas, Rebecca L. Olin, Aaron C Logan
Clinical Cancer Research. 2019-08-15
720 citations
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta
Science Translational Medicine. 2015-11-25

Journal Articles

Prevalence and Impact of De Novo DSA During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients
Sandy Feng, Josh Levitsky, Peter Sayre, Matthew J Everly, Abraham Shaked, Hepatology

Abstracts/Posters

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Peter H. Sayre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019